Company intelligence / Profile preview

O-Genesis

Taipei, Taiwan

Ownership: Private
Development stage: Other

Overview

O-Genesis is a clinical-stage biotechnology company specializing in regenerative medicine and advanced cell therapies. The company leverages its proprietary O-Cell platform to develop adipose-derived stem cell (ADSC) treatments for chronic and hard-to-heal wounds. Its lead program, OG-01, is currently being evaluated in clinical trials for the treatment of diabetic foot ulcers. O-Genesis aims to provide innovative solutions for tissue repair and regeneration through standardized, high-quality cell products. The company's technology focuses on enhancing the regenerative potential of stem cells to promote angiogenesis and accelerate healing in patients with metabolic and vascular complications.

Therapeutic areas: EndocrinologyDermatology
Modalities: Cell therapyStem cell therapy
Industry: Biotech

Drug pipeline

1 asset

O-Genesis

Unknown

Beyond the preview

Go deeper on O-Genesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on O-Genesis.

Explore the full profile